|
|
 |
|
Viewing report
|
|
|
|
Commercial and Pipeline Perspectives: Rheumatoid Arthritis - Novel Biologics Drive Innovation in the Global RA Market
Datamonitor, June 2004, Pages: 230
Introduction
Enbrel (etanercept) and Remicade (infliximab) dominate the US and European RA markets, accounting for more than 80% of value sales; in Japan Remicade competes with sales of traditional DMARDs. Market success could rely on finding new inflammatory indications. Pfizers COX-2 portfolio will out-perform Mercks, as side-effect issues and product approval delays hit Vioxx and Arcoxia, respectively.
Scope
The RA market is defined for the purposes of this report as the ATC4 classes M1C0, M1A1, M1A3, L4A0 (Remicade and Prograf only), L1X3 (Rituxan only)
The ten year forecast is based on four years of IMS sales data, extrapolated using a dampened time series methodology and adjusted for market events
The forecast is split into the major markets: US, Japan, France, Germany, Italy, Spain and UK; with Global and European regional totals also provided
Pipeline, late phase, DMARD and NSAID therapies are profiled in detail using a new, enhanced, quantitative SWOT benchmarking framework
Highlights
Approval in additional indications will lessen the impact on Remicade (infliximab) of new biologic DMARD launches, commencing in 2006. Late-phase pipeline candidates are beginning trials for non-core indications before launch in the core indication to maximize revenues over the lifecycle of the compound.
CDP 870, Rituxan and CTLA4-Ig are the most commercially promising pipeline DMARDs. Sales are predicted to follow the exponential growth curves of Enbrel (etanercept) and Remicade (infliximab) with long take-up phases. Current late-stage candidates address the unmet need of dosing frequency, but an opportunity remains for an effective oral DMARD.
Prospects for Amgens portfolio remain strong, but continued success depends on the impact of patent expiry. Biogeneric erosion of Enbrel, the first biologic DMARD to go off patent in the US, in 2009, would force Amgen to push new candidates, such as Humax IL-15, currently in Phase II, to fill the revenue gap left by under-performing Kineret.
Reasons to Purchase
Follow the commercial success of Remicade use the PowerPoint presentation to share key market insight
Identify market potential for pipeline products access country-specific sales forecasts for the 7 major markets in an interactive Excel database
Plan lifecycle management strategies to achieve market success understand the key events that will shape the sector
Customers who bought this item also bought
Pipeline Insight: Rheumatoid Arthritis and Osteoarthritis - Striving for innovation among me-toos
Commercial and Pipeline Perspectives: Lower GI Disorders - Remicade Leads Growth as Novel Biologics Compete for Market Share in Inflammatory Bowel Disease
Osteoarthritis and Rheumatoid Arthritis: Opinion Leader Forum - Experts Views and Perspectives on Diagnosis, Treatment, Product Performance and Closing the Need Gap
Treatment Algorithms: Rheumatoid Arthritis 2nd Edition - Dmards Move to Front of Pack
Rheumatoid arthritis: Emerging drug discovery targets and therapeutic candidates
Pipeline and Commercial Perspectives: Psoriasis and Atopic Dermatitis - Reimbursement the key as biologics and TIMs transform disease markets
Market Dynamics: Arthritis - The Ongoing Battle for Supremacy
Epidemiology: Osteo and Rheumatoid Arthritis - Defining the patient populations
|
|
|
|
